Medication

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Friday, June 2, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Medication, Epilepsy, Common stock, Employment, Therapy, Compensated emancipation, Pharmaceutical industry, Lease

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees.

Key Points: 
  • (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees.
  • The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 72,825 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • These stock option grants have an exercise price of $7.22 per share, which is equal to the closing price of the Common Stock on June 1, 2023 (date of grant for such stock options).
  • The stock options were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023

Retrieved on: 
Friday, June 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Psych, Teva Pharmaceuticals, Interim, Risk, VMAT2, TEVA, Global R&D management, START, Teva, Use, TD, De novo, State University of New York Upstate Medical University, Safety, Efficacy, Clinical Global Impression, Doctor of Philosophy, Patient, Medication, PGIC, Tablet, Congress, DE, User experience, MD, Poster, Randomness, TASE, Olanzapine, Annual general meeting, Chorea, Treatment, AM, Effectiveness, Reactions on surfaces, XR, FDA, Mental health, Tardive dyskinesia, NYSE, SHINE, Pharmaceutical industry, Nursing, Tolerability, Schizophrenia

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its neuroscience portfolio featured at the Psych Congress Elevate 2023 Annual Meeting taking place on June 1-4, 2023.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its neuroscience portfolio featured at the Psych Congress Elevate 2023 Annual Meeting taking place on June 1-4, 2023.
  • Two presentations feature real-world data for AUSTEDO (deutetrabenazine) tablets for adults living with TD.
  • Data presented will include interim findings from the START trial, a Phase 4 study investigating real-world utilization of AUSTEDO with a 4-week patient titration kit along with treatment success as measured at the end of treatment.
  • Teva will also present findings from studies evaluating potential drug-drug interactions with VMAT2 inhibitors, as well as patient and healthcare provider perspectives on the impact of TD.

Better Minds Group Welcomes Amy Klinger, MSN, FNP-BC, Prescribing Nurse Practitioner, to work in collaboration with Better Minds Group Psychotherapists

Retrieved on: 
Friday, June 2, 2023
Depression, MSN, Anxiety, Psychotherapy, ADHD, ANCC, Alcoholism, Otterbein University, Addiction medicine, Insomnia, MAT, American Nurses Credentialing Center, Recovery, Family nurse practitioner, Trauma, Medication, Bipolar disorder, Nursing, Science

She is offering medication-assisted treatment (MAT) programs, harm-reduction techniques, and we are proud to announce, bringing the Sinclair Method to our community.

Key Points: 
  • She is offering medication-assisted treatment (MAT) programs, harm-reduction techniques, and we are proud to announce, bringing the Sinclair Method to our community.
  • "I was drawn to Better Minds Group because I want to work together with psychotherapists.
  • Amy graduated from Otterbein University with her Master of Science in Nursing specializing in a Family Nurse Practitioner degree.
  • Amy is the Founder and President of Recovery NP, an addiction medicine practice based in Granville, Ohio.

Trajan's Microsampling Devices Meet IVDR Compliance in Europe, UK

Retrieved on: 
Friday, June 2, 2023
Medicine, IVDR, Health, Mitra, Medication, Research, DBS, MHRA, Medicines and Healthcare products Regulatory Agency, Safety, Medical device, Trajan

MELBOURNE, Australia, June 2, 2023 /PRNewswire/ -- Trajan Scientific and Medical, a leading provider of analytical and life sciences products and solutions, today announced the regulatory approval of its Neoteryx remote blood microsampling devices, Mitra® and hemaPEN® for clinical use in Europe and the United Kingdom.

Key Points: 
  • Trajan has successfully fulfilled the required product safety and performance requirements under the In Vitro Diagnostic Medical Devices Regulation (IVDR) in Europe and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom.
  • Having earned this CE Mark regulatory compliance, Trajan expands the capabilities of its Neoteryx® microsampling products to provide decentralised, person-centered, minimally invasive blood collection in both clinical and research settings.
  • Mitra® and hemaPEN® devices can be used remotely to collect blood samples through an easy, virtually painless process.
  • "The updated regulatory approval of Trajan's blood microsampling devices in the UK and European Union is another step forward towards our vision of personalized, preventative data-based healthcare," said Stephen Tomisich, CEO and founder of Trajan.

Trajan's Microsampling Devices Meet IVDR Compliance in Europe, UK

Retrieved on: 
Friday, June 2, 2023
Medicine, IVDR, Health, Mitra, Medication, Research, DBS, MHRA, Medicines and Healthcare products Regulatory Agency, Safety, Medical device, Trajan

MELBOURNE, Australia, June 2, 2023 /PRNewswire/ -- Trajan Scientific and Medical, a leading provider of analytical and life sciences products and solutions, today announced the regulatory approval of its Neoteryx remote blood microsampling devices, Mitra® and hemaPEN® for clinical use in Europe and the United Kingdom.

Key Points: 
  • Trajan has successfully fulfilled the required product safety and performance requirements under the In Vitro Diagnostic Medical Devices Regulation (IVDR) in Europe and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom.
  • Having earned this CE Mark regulatory compliance, Trajan expands the capabilities of its Neoteryx® microsampling products to provide decentralised, person-centered, minimally invasive blood collection in both clinical and research settings.
  • Mitra® and hemaPEN® devices can be used remotely to collect blood samples through an easy, virtually painless process.
  • "The updated regulatory approval of Trajan's blood microsampling devices in the UK and European Union is another step forward towards our vision of personalized, preventative data-based healthcare," said Stephen Tomisich, CEO and founder of Trajan.

Mix Talent Launches Contract Talent Organization Solution, Mix CTO

Retrieved on: 
Thursday, June 1, 2023
GSK, Business development, Gene, Life, Medication, Bristol Myers Squibb, Mix, Organization, Syneos Health, Association of British HealthTech Industries, Johnson & Johnson, Management, Publicis, Shionogi, IQVIA, Biotechnology, Bayer, COLUMBUS

COLUMBUS, Ohio, June 1, 2023 /PRNewswire/ -- Since 2018, Mix Talent has been helping life sciences companies – including Pharmaceutical, Biotech, HealthTech, and Gene Therapy organizations – recruit, assess, optimize, scale, and develop their talent. In that time, Mix has supported over 300 projects for more than 200 life sciences clients, building a team of over 100 in the process. 

Key Points: 
  • The life sciences talent leader has assembled a team of industry veterans to provide greater flexibility through their new contract talent solutions.
  • Now, in response to a competitive, challenging life sciences market and customer demand, Mix is launching a new solution: Mix CTO (Contract Talent Organization).
  • Mix CTO will provide life sciences organizations with rapid access to top talent spanning pre-commercial, medical affairs and sales organizations along with contingent talent augmentation for growing companies.
  • "With the highly experienced team of strategists, thought leaders, and recruiters we have gathered at Mix, providing Mix CTO to our clients is an important addition to our comprehensive talent solutions and we're extremely excited about it," says Mickey Shimp, President of Mix Talent.

Biocytogen Opens San Francisco Office to Accelerate Globalization

Retrieved on: 
Wednesday, May 31, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Medication, HKEX, Pharmaceutical industry

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has announced the opening of a new office in San Francisco, California, USA.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has announced the opening of a new office in San Francisco, California, USA.
  • The new space will aim to accelerate the globalization of Biocytogen’s businesses.
  • San Francisco is renowned as a hub of the biotechnology industry, and is home to several renowned biopharmaceutical companies.
  • Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “The opening of the San Francisco office will strengthen our global business development and accelerate the realization of our vision – to become a global headstream of new drugs.

Biocytogen Opens San Francisco Office to Accelerate Globalization

Retrieved on: 
Wednesday, May 31, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Medication, HKEX, Pharmaceutical industry

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has announced the opening of a new office in San Francisco, California, USA.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has announced the opening of a new office in San Francisco, California, USA.
  • The new space will aim to accelerate the globalization of Biocytogen’s businesses.
  • San Francisco is renowned as a hub of the biotechnology industry, and is home to several renowned biopharmaceutical companies.
  • Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “The opening of the San Francisco office will strengthen our global business development and accelerate the realization of our vision – to become a global headstream of new drugs.

Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease

Retrieved on: 
Wednesday, May 31, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Regenerative Medicine Advanced Therapy, Marketing, Pharming, European Medicines Agency, Quality of life, Risk assessment, Fast Track, MBA, Cardiology, AAV, RP, Disorder, PRIME, Medication, EMA, Troponin I, New York Heart Association Functional Classification, Patient, BNP, Danon disease, Pharmaceutical industry

PRIME designation offers the benefits of early and enhanced support from the EMA for the development of medicines that target unmet medical needs, as well as the opportunity for an accelerated review of the marketing application.

Key Points: 
  • PRIME designation offers the benefits of early and enhanced support from the EMA for the development of medicines that target unmet medical needs, as well as the opportunity for an accelerated review of the marketing application.
  • Rocket was also recently granted Regenerative Medicine Advanced Therapy (RMAT) designation for its RP-A501 program, which also holds Fast Track , Orphan Drug (U.S.) and Rare Pediatric designations.
  • “PRIME designation from the EMA further highlights the positive benefit/risk profile of RP-A501 in addressing the critical unmet need of patients facing Danon Disease,” said Kinnari Patel, Pharm.D., MBA, President and Chief Operating Officer, Rocket Pharma.
  • The results demonstrated improvements and/or normalization across multiple quantifiable parameters that cardiologists use in clinical practice to enable risk assessment and treatment decisions.

Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference

Retrieved on: 
Wednesday, May 31, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Medication, Viral, Webcast, Conference, Pharmaceutical industry, Broadcasting

Enanta Pharmaceuticals, Inc .

Key Points: 
  • Enanta Pharmaceuticals, Inc .
  • (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Jefferies Global Healthcare Conference on June 7, 2023 at 12:30 p.m.
  • A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com .
  • A replay of the webcast will be available following the presentation and will be archived for at least 30 days.